Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.730
0.00 (0.00%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Inventiva Revenue
Inventiva had revenue of 2.73M EUR in the half year ending June 30, 2024, a decrease of -19.40%. This brings the company's revenue in the last twelve months to 19.28M, down -12.56% year-over-year. In the year 2023, Inventiva had annual revenue of 23.16M with 23.12% growth.
Revenue (ttm)
19.28M EUR
Revenue Growth
-12.56%
P/S Ratio
n/a
Revenue / Employee
156,707 EUR
Employees
123
Market Cap
248.11M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Puma Biotechnology | 219.14M |
InfuSystem Holdings | 129.37M |
Repare Therapeutics | 68.68M |
Verastem | 10.00M |
EUDA Health Holdings | 3.81M |
Inovio Pharmaceuticals | 591.86K |
Checkpoint Therapeutics | 78.00K |
IVA News
- 1 day ago - Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 8 days ago - Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants - GlobeNewsWire
- 8 days ago - Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Benzinga
- 9 days ago - Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report - GlobeNewsWire
- 9 days ago - Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study - GlobeNewsWire
- 27 days ago - Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results - GlobeNewsWire
- 2 months ago - Inventiva Reports Preliminary 2024 First-Half Financial Information¹ - GlobeNewsWire
- 3 months ago - Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor - GlobeNewsWire